Product Description
Ceftriaxone is used to treat bacterial infections in many different parts of the body. This medicine is also given before certain types of surgery to prevent infections. Ceftriaxone belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/ceftriaxone-injection-route/description/drg-20073123)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Thomas Benfield
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Kenya, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Appendicitis|Bronchitis|COVID-19|Fractures, Open|Hidradenitis Suppurativa|Influenza, Human|Peritonitis|Pneumonia|Pneumonia, Ventilator-Associated|Respiratory Tract Infections|Urinary Tract Infections
Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Coinfection|Community-Acquired Infections|Dementia|Parkinson's Disease|Pyelonephritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DURATIOM | P3 |
Unknown Status |
Fractures, Open |
2027-12-31 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|COVID-19|Influenza, Human |
2026-02-01 |
|
| ABCESS2 | P3 |
Not yet recruiting |
Hidradenitis Suppurativa |
2025-12-15 |
|
| BRICEFA20170414 | P2 |
Recruiting |
Dementia|Parkinson's Disease |
2024-12-31 |
32% |